Targeted
protein degradation (TPD) is an emerging technique for
protein regulation. Currently, all TPD developed in eukaryotic cells
relies on either ubiquitin-proteasome or lysosomal systems, thus are
powerless against target proteins in membrane organelles lacking proteasomes
and lysosomes, such as mitochondria. Here, we developed a mitochondrial
protease targeting chimera (MtPTAC) to address this issue. MtPTAC
is a bifunctional small molecule that can bind to mitochondrial caseinolytic
protease P (ClpP) at one end and target protein at the other. Mechanistically,
MtPTAC activates the hydrolase activity of ClpP while simultaneously
bringing target proteins into proximity with ClpP. Taking mitochondrial
RNA polymerase (POLRMT) as a model protein, we have demonstrated the
powerful proteolytic ability and antitumor application prospects of
MtPTAC, both in vivo and in vitro. This is the first modularly designed TPD that can specifically
hydrolyze target proteins inside mitochondria.